Medicus Pharma MDCX 深 滬
等待開盤 07-23 09:30:00 美东时间
0.3745
-0.013
-3.40%
華盛通- 最 高0.381
- 今 開0.3727
- 成交量 58.44万股
- 最 低 0.3536
- 昨 收 0.3877
- 總市值 2121.85万
- 52周最高 3.05
- 市盈率 靜 --
- 換手率 1.03%
- 52周最低 0.25
- 委 比 -54.70%
- 總股本 5665.82万
- 歷史最高 8.94
- 量 比 0.42
- 振 幅 7.07%
- 歷史最低 0.25
- 每 手 1
- 風險率 0.87%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Medicus Pharma Announces Positive FDA Feedback For Its Optimized Phase 2 Clinical Trial Of Teverelix In Men Following A First Episode Of Acute Urinary Retention
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that it has received written feedback from the U.S. Food and Drug Administrat...
07-16 19:33
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
Medicus Pharma Ltd. announced FDA feedback and IRB approval for its optimized Phase 2 study of Teverelix® for preventing recurrent acute urinary retention in men. The redesigned study, ANT-2111-02, will enroll ~126 patients (down from ~390) and evaluate Teverelix DP's effects on prostate volume and urinary function. The study aims to generate decision-grade evidence, optimize dose and route, and support future development and partnerships. FDA re...
07-16 11:30
Medicus Pharma To Present Showcase SkinJect Registrational Strategy, Teverelix Precision Medicine Program At 2026 Bio International Conference
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that it will participate in the 2026 Bio International Conference, being hel...
06-22 19:37
Medicus Pharma Submits IND Application To DOH For PRECISION-E2, Phase 2a Genomics-Enabled Clinical Trial Evaluating Teverelix In Women With Symptomatic Endometriosis In UAE
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced submission of an Investigational New Drug (IND) application to the Department...
06-11 19:34
Medicus Pharma Submits Protocol SKNJCT-005 To FDA Under Existing IND Application, For SkinJect Into Registrational Development For Patients With Gorlin Syndrome
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today
06-03 20:06
Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome
Medicus Pharma submitted a Phase 2b protocol to the FDA for SkinJect®, targeting patients with Gorlin Syndrome, a rare genetic disorder causing multiple basal cell carcinomas. The study aims to assess efficacy and safety, potentially leading to FDA approval as the first lesion-directed therapy for this population. The company also applied for Orphan Drug Designation and Rare Pediatric Disease Priority Review Voucher, which could expedite approval...
06-03 12:00
Medicus Pharma Receives $22M In Non-Dilutive Financing
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today
05-28 20:19
Medicus Pharma Q1 EPS $(0.31) Misses $(0.19) Estimate
Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.19) by 63.16 percent. This is a 26.19 percent increase over losses of $(0.42) per share from
05-15 04:34
